Phase 2/3 Efficacy and Safety of PP405 in Adult Males
A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2/3 Study to Assess Efficacy and Long-Term Safety of PP405 in Adult Males With Androgenetic Alopecia
In the register
The register attaches this trial to PP405 (Pelage Pharmaceuticals), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 2/3
- Sponsor
- Pelage Pharmaceuticals, Inc.
- Participants (registry)
- 600
- Start
- September 2026
- Primary completion
- December 2027 (planned)
- Study completion
- June 2028 (planned)
- Last registry update
- October 2026
- Countries
- United States, Canada
Conditions studied: Androgenetic Alopecia
Interventions: PP405 0.05% Topical Gel, PP405, Vehicle Topical Gel, Vehicle
Other trials of PP405
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.